Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Cerus Corp. Logo

ARKK Holdings of Cerus Corporation (CERS) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
December 27, 2021SELL34.215k0.0014%ARKK
August 24, 2020SELL138.208k0.008%ARKK
  • 1
  • 5 / page

Key Statistics

Upcoming EarningsSee Full Calendar
DateFebruary 23, 2022(Est)Revenue
Expected$43.90m
Actual▫️
EPS
Expected-$0.08
Actual▫️
🕵🏼Found In🏷Last Price
ARKKARKG$4.96
⚖️Weighting🧢Market Cap
0.42%$855.30m
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
357.18
🏋️‍♀️Weight Rank Across All Funds🌏Country
55🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$3.255.68%
Description
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
Website
www.cerus.com

Research Notes and Commentary for CERS